iclusig
incyte biosciences distribution b.v. - ponatinib - leukemia, myeloid; leukemia, lymphoid - antineoplastic agents, protein kinase inhibitors - iclusig is indicated in adult patients withchronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (cml) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutationphiladelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutation. veja as seções 4. 2 assessment of cardiovascular status prior to start of therapy and 4. 4 situations where an alternative treatment may be considered.
iclusig
pint pharma produtos medico-hospitalares e farmaceuticos ltda - cloridrato de ponatinibe - agentes antineoplÁsicos
itraconazol
eurofarma laboratÓrios s.a. - itraconazol - antimicoticos sistemicos
itraconazol
prati donaduzzi & cia ltda - itraconazol - antimicoticos sistemicos
gastrium
achÉ laboratÓrios farmacÊuticos s.a - omeprazol - antiacidos e antiulcerosos
itraconazol generis 100 mg cápsulas
generis farmacêutica, s.a. - itraconazol - cápsula - 100 mg - itraconazol 100 mg - itraconazole - genérico - duração do tratamento: longa duração
itraconazol generis 100 mg cápsulas
generis farmacêutica, s.a. - itraconazol - cápsula - 100 mg - itraconazol 100 mg - itraconazole - genérico - duração do tratamento: longa duração
itraconazol generis 100 mg cápsulas
generis farmacêutica, s.a. - itraconazol - cápsula - 100 mg - itraconazol 100 mg - itraconazole - genérico - duração do tratamento: longa duração
itraspor
ems sigma pharma ltda - antimicotico
sporanox
janssen-cilag farmacÊutica ltda - itraconazol - antimicoticos sistemicos